Lung cancer patients in England to receive Amgen drug that targets a gene mutation
(VOVWORLD) - Lung cancer patients in England will become the first in Europe to receive a drug made by US biotech Amgen that targets a specific gene mutation, the country's health service said on Friday.
.
 An Amgen sign is seen at the company's office in South San Francisco, California, October 21, 2013. (Photo: REUTERS/Robert Galbraith) |
NHS England said it was fast-tracking lung cancer drug sotorasib after it was shown in clinical trials to stop lung cancer progression for seven months.
The drug, taken as a tablet, will be used on patients with the KRAS G12C mutation that occurs in about 13% of non-small cell lung cancers the most common type of lung cancer.
The early-access deal will see 600 patients a year receive sotorasib in England through the state-run National Health Service (NHS).
"This revolutionary treatment has taken decades of research to reach the clinic, and now that it is here this new targeted drug will be available for eligible people with lung cancer as quickly as possible thanks to this agreement," said Peter Johnson, NHS clinical director for cancer.
Charles Swanton, chief clinician at charity Cancer Research UK, said the drug was "one of the most exciting breakthroughs in lung cancer treatment in 20 years, targeting a cancer gene that was previously untargetable."